FY2025 EPS Estimates for Globus Medical, Inc. Increased by Zacks Research (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research boosted their FY2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Monday, May 6th. Zacks Research analyst R. Department now forecasts that the medical device company will post earnings of $2.89 per share for the year, up from their previous estimate of $2.88. The consensus estimate for Globus Medical’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2025 earnings at $0.67 EPS.

GMED has been the subject of several other reports. Truist Financial boosted their price objective on shares of Globus Medical from $58.00 to $60.00 and gave the company a “hold” rating in a report on Wednesday, February 21st. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a research note on Wednesday. Piper Sandler lifted their price objective on Globus Medical from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Wednesday. BTIG Research upped their price objective on Globus Medical from $60.00 to $63.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Stifel Nicolaus upped their price objective on Globus Medical from $64.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.60.

Globus Medical Price Performance

NYSE GMED opened at $61.61 on Wednesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.72 and a current ratio of 4.88. The company has a market capitalization of $8.34 billion, a price-to-earnings ratio of 52.66, a PEG ratio of 1.53 and a beta of 1.11. The stock has a 50-day moving average of $52.50 and a 200 day moving average of $51.26. Globus Medical has a one year low of $43.38 and a one year high of $65.74.

Globus Medical (NYSE:GMED) last issued its earnings results on Tuesday, May 7th. The medical device company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.17. Globus Medical had a net margin of 7.83% and a return on equity of 8.82%. The business had revenue of $606.67 million during the quarter, compared to analysts’ expectations of $586.82 million. During the same period in the previous year, the company earned $0.53 earnings per share. The business’s revenue for the quarter was up 119.3% compared to the same quarter last year.

Hedge Funds Weigh In On Globus Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Globus Medical by 49.7% in the 3rd quarter. Vanguard Group Inc. now owns 11,245,502 shares of the medical device company’s stock valued at $558,339,000 after purchasing an additional 3,732,959 shares during the last quarter. Norges Bank purchased a new position in Globus Medical during the 4th quarter worth $95,537,000. Paradice Investment Management LLC purchased a new position in Globus Medical during the 3rd quarter worth $55,053,000. Bank of New York Mellon Corp increased its holdings in Globus Medical by 80.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,406,682 shares of the medical device company’s stock worth $119,492,000 after purchasing an additional 1,069,419 shares during the period. Finally, Nuance Investments LLC increased its holdings in Globus Medical by 36.8% during the 3rd quarter. Nuance Investments LLC now owns 3,620,518 shares of the medical device company’s stock worth $179,759,000 after purchasing an additional 974,693 shares during the period. 95.16% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Leslie V. Norwalk sold 10,590 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $51.99, for a total value of $550,574.10. Following the completion of the transaction, the director now owns 17,419 shares of the company’s stock, valued at $905,613.81. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 24.30% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.